Placental Transfer of Tranexamic Acid and the Case for Earlier Use in Obstetric Hemorrhage Trials

The current practice of delaying tranexamic acid administration until after cord clamping may blunt its therapeutic potential in obstetric hemorrhage. Although this precaution aims to avoid fetal exposure, pharmacokinetic and available safety data suggest that such exposure poses minimal fetal risk. Data from limited cesarean and placenta previa studies indicate that earlier administration-before surgical incision or onset of bleeding-may reduce blood loss without harming neonates. Given that tranexamic acid is most effective when given early or before the onset of fibrinolysis, obstetric clinical trials and future protocols should reconsider the current default to post-cord clamping dosing. Earlier, targeted tranexamic acid administration may improve maternal outcomes without compromising neonatal safety and should be considered part of a rational approach in obstetric hemorrhage clinical trials.